The Swiss drug delivery device maker says the two new 1 mL and 2.25 mL platforms enable material recovery. Their design enables automated disassembly and efficient recycling while offering the convenience of a pre-filled, two-step autoinjector.
Ypsomed said the YpsoLoop platform integrates into existing production environments. This supports a transition toward more sustainable drug delivery solutions. The company followed eco-design principles and kept circularity in mind during the design process, it said.
Both the device structure and material selection enable automated disassembly so materials can be separated, recovered and reintroduced into the material cycle, rather than discarded as waste. The platform has two mono-material subassemblies (one for the syringe and one for the drive unit) to enable efficient recycling.
Ypsomed says its bio-based and sustainable materials achieve an estimated 87% reduction in material-related CO₂ emissions compared with conventional autoinjectors.
Prior to the sale of its diabetes business to TecMed, Ypsomed was one of the largest diabetes technology units in the world — see our full list HERE.)
Beyond sustainability, the company built the device on its long-standing experience in self-injection systems, like the YpsoMate system. It features ClickGuide technology to provide continuous acoustic feedback throughout the injection process. This helps users maintain their recommended holding time and reduces the risk of early lift-offs.
The system also has an ergonomically shaped cap to facilitate easy removal while strengthening confidence in self-administration. Ypsomed hopes to support consistent dosing and adherence across diverse patient groups.
YpsoLoop also integrates into existing fill/finish and assembly setups, including those for YpsoMate. Now, pharmaceutical companies and contract manufacturers can adopt the new platform with only minor modifications, the company says.
“With YpsoLoop, we are taking an important step toward a more circular approach in healthcare,” said Ulrike Bauer, Chief Business Officer at Ypsomed. “Achieving circularity requires collaboration across the entire value chain – from device manufacturers and pharma partners to patients. This platform provides the basis for sustainable self-injection solutions that combine usability, safety, and environmental responsibility.”
